Revance Therapeutics, Inc.

Revance Therapeutics develops neuromodulators for aesthetic and therapeutic uses in the US and internationally. Its lead candidate is DAXXIFY for treating glabellar lines and cervical dystonia. It has completed Phase II trials for upper facial lines, forehead lines, lateral canthal lines, adult spasticity, and plantar fasciitis. The company also develops OnabotulinumtoxinA, a BOTOX biosimilar in preclinical stage, and offers RHA dermal fillers for dynamic wrinkles and perioral rhytids. It has a collaboration with Viatris Inc. to develop onabotulinumtoxinA.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

3.6 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0